A randomized, placebo‐controlled study of the NS 5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1

Beclabuvir is a potent, non‐nucleoside inhibitor of the HCV NS 5B RNA polymerase, with nanomolar activity against HCV genotypes 1, 3, 4, 5 and 6 in vitro . This study evaluated the efficacy and safety of beclabuvir, in combination with peginterferon alfa‐2a (peg IFN ) and ribavirin ( RBV ), in HCV g...

Full description

Saved in:
Bibliographic Details
Published in:Journal of viral hepatitis 2015-08, Vol.22 (8), p.658-664
Main Authors: Tatum, H., Thuluvath, P. J., Lawitz, E., Martorell, C., DeMicco, M., Cohen, S., Rustgi, V., Ravendhran, N., Ghalib, R., Hanson, J., Zamparo, J., Zhao, J., Cooney, E., Treitel, M., Hughes, E.
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Beclabuvir is a potent, non‐nucleoside inhibitor of the HCV NS 5B RNA polymerase, with nanomolar activity against HCV genotypes 1, 3, 4, 5 and 6 in vitro . This study evaluated the efficacy and safety of beclabuvir, in combination with peginterferon alfa‐2a (peg IFN ) and ribavirin ( RBV ), in HCV genotype 1. In this randomized (1:1:1), double‐blinded, placebo‐controlled, dose‐ranging phase 2a study, 39 treatment‐naive patients chronically infected with HCV genotype 1 were treated for 48 weeks with beclabuvir (75 mg or 150 mg) plus peg IFN (180 μg) and RBV (1000 mg/day [
ISSN:1352-0504
1365-2893
DOI:10.1111/jvh.12372